Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
08
2022
accepted:
23
09
2022
revised:
14
09
2022
pubmed:
14
10
2022
medline:
28
10
2022
entrez:
13
10
2022
Statut:
ppublish
Résumé
Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and therapeutic advances. Moreover, patients with GCTs are treated by different medical professionals including paediatric oncologists, neuro-oncologists, medical oncologists, neurosurgeons, gynaecological oncologists, surgeons, and urologists. Silos of care have thus formed, further hampering knowledge dissemination between specialists. Dedicated biobank specimen collection is therefore critical to foster continuous growth in our understanding of similarities and differences by age, gender, and site, particularly for rare cancers such as GCTs. Here, the Malignant Germ Cell International Consortium provides a framework to create a sustainable, global research infrastructure that facilitates acquisition of tissue and liquid biopsies together with matched clinical data sets that reflect the diversity of GCTs. Such an effort would create an invaluable repository of clinical and biological data which can underpin international collaborations that span professional boundaries, translate into clinical practice, and ultimately impact patient outcomes.
Identifiants
pubmed: 36229581
doi: 10.1038/s41416-022-02000-4
pii: 10.1038/s41416-022-02000-4
pmc: PMC9596690
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1583Informations de copyright
© 2022. The Author(s).
Références
Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer. 2010;116:4882–91.
pubmed: 20597129
doi: 10.1002/cncr.25454
Fonseca A, Frazier AL, Shaikh F. Germ cell tumors in adolescents and young adults. J Oncol Pract. 2019;15:433–41.
pubmed: 31404512
doi: 10.1200/JOP.19.00190
Barr RD, Ries LA, Lewis DR, Harlan LC, Keegan TH, Pollock BH, et al. Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “nonmalignant/noninvasive” tumors. Cancer. 2016;122:1000–8.
pubmed: 26848808
doi: 10.1002/cncr.29867
Oosterhuis JW, Looijenga LHJ. Human germ cell tumours from a developmental perspective. Nat Rev Cancer. 2019;19:522–37.
pubmed: 31413324
doi: 10.1038/s41568-019-0178-9
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. Andrology. 2015;3:4–12.
pubmed: 25331326
doi: 10.1111/andr.293
Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18:1022–39.
pubmed: 28687376
doi: 10.1016/S1470-2045(17)30445-X
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144:405–13.
pubmed: 27931752
doi: 10.1016/j.ygyno.2016.10.019
Frappaz D, Dhall G, Murray MJ, Goldman S, Faure Conter C, Allen J, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro-Oncology. 2021;24:516–27.
Lobo J, Gillis AJM, Jeronimo C, Henrique R, Looijenga LHJ. Human germ cell tumors are developmental cancers: impact of epigenetics on pathobiology and clinic. Int J Mol Sci. 2019;20:258.
Murray MJ, Nicholson JC, Coleman N. Biology of childhood germ cell tumours, focussing on the significance of microRNAs. Andrology. 2015;3:129–39.
pubmed: 25303610
doi: 10.1111/andr.277
Muller MR, Skowron MA, Albers P, Nettersheim D. Molecular and epigenetic pathogenesis of germ cell tumors. Asian J Urol. 2021;8:144–54.
pubmed: 33996469
doi: 10.1016/j.ajur.2020.05.009
Ronchi A, Cozzolino I, Montella M, Panarese I, Zito Marino F, Rossetti S, et al. Extragonadal germ cell tumors: not just a matter of location. A review about clinical, molecular and pathological features. Cancer Med. 2019;8:6832–40.
pubmed: 31568647
pmcid: 6853824
doi: 10.1002/cam4.2195
Lafin J, Bagrodia A, Woldu S, Amatruda J. New insights into germ cell tumor genomics. Andrology. 2019;7:507–15.
pubmed: 30896089
Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, et al. Testicular cancer. Nat Rev Dis Prim. 2018;4:29.
pubmed: 30291251
doi: 10.1038/s41572-018-0029-0
Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 2018;23:3392–406.
pubmed: 29898407
pmcid: 6075738
doi: 10.1016/j.celrep.2018.05.039
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762–74.
pubmed: 26651223
doi: 10.1016/S0140-6736(15)00991-5
Garcia M, Downs J, Russell A, Wang W. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. 2018;13:1–13.
doi: 10.1186/s13023-018-0942-z
Lobo J, Jeronimo C, Henrique R. Morphological and molecular heterogeneity in testicular germ cell tumors: implications for dedicated investigations. Virchows Arch. 2021;479:865–6.
pubmed: 34417634
doi: 10.1007/s00428-021-03194-3
Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol. 2015;16:e470–e7.
pubmed: 26370356
doi: 10.1016/S1470-2045(15)00244-2
Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1–iv18.
pubmed: 32169220
doi: 10.1093/annonc/mdy001
Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol. 2016;17:e149–62.
pubmed: 27300675
doi: 10.1016/S1470-2045(15)00545-8
Zika E, Paci D, Bäumen T, Braun A. Biobanks in Europe: prospects for harmonisation and networking, JRC scientific and technical reports. Luxembourg: Publications Office of the European Union; 2010.
Hainaut P, Vaught J, Zatloukal K, Pasterk M. Biobanking of human biospecimens. Cham: Springer Cham; 2021.
Ci B, Yang DM, Krailo M, Xia C, Yao B, Luo D, et al. Development of a data model and data commons for germ cell tumors. JCO Clin Cancer Inform. 2020;4:555–66.
pubmed: 32568554
doi: 10.1200/CCI.20.00025
Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, et al. The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). Br J Cancer. 2021;124:368–74.
pubmed: 32989229
doi: 10.1038/s41416-020-01075-1
Ci B, Lin S-Y, Yao B, Luo D, Xu L, Krailo M, et al. Developing and using a data commons for understanding the molecular characteristics of germ cell tumors. In: Bagrodia A, Amatruda JF, editors. Testicular germ cell tumors. Methods in molecular biology. New York: Humana; 2021. p. 263–75.
Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun. 2021;12:4487.
pubmed: 34301922
pmcid: 8302763
doi: 10.1038/s41467-021-24334-y
Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, et al. Code of practice needed for samples donated by trial participants. Lancet Oncol. 2022;23:e89–e90.
pubmed: 35240091
doi: 10.1016/S1470-2045(22)00059-6
Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation. EPMA J. 2016;7:1–12.
Gottweis H, Lauss G. Biobank governance: heterogeneous modes of ordering and democratization. J Community Genet. 2012;3:61–72.
pubmed: 22147279
doi: 10.1007/s12687-011-0070-0
Dupont J-CK, Pritchard-Jones K, Doz F. Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review. Lancet Oncol. 2016;17:e187–97.
pubmed: 27301046
doi: 10.1016/S1470-2045(16)00142-X
Staunton C, Slokenberga S, Mascalzoni D. The GDPR and the research exemption: considerations on the necessary safeguards for research biobanks. Eur J Hum Genet. 2019;27:1159–67.
pubmed: 30996335
pmcid: 6777499
doi: 10.1038/s41431-019-0386-5
Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol. 2008;9:485–93.
pubmed: 18452859
doi: 10.1016/S1470-2045(08)70128-1
Massimo LM, Wiley TJ, Casari EF. From informed consent to shared consent: a developing process in paediatric oncology. Lancet Oncol. 2004;5:384–7.
pubmed: 15172360
doi: 10.1016/S1470-2045(04)01496-2
Stoneham SJ, Hale JP, Rodriguez‐Galindo C, Dang H, Olson T, Murray M, et al. Adolescents and young adults with a “rare” cancer: getting past semantics to optimal care for patients with germ cell tumors. London: Oxford University Press; 2014. p. 689–92.
Heidenreich A. Interdisciplinary management of testicular germ cell tumors - more needed than ever! Oncol Res Treat. 2018;41:354–5.
pubmed: 29763920
doi: 10.1159/000489719
Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018;29:341–6.
pubmed: 29140422
doi: 10.1093/annonc/mdx731
Paskal W, Paskal AM, Dębski T, Gryziak M, Jaworowski J. Aspects of modern biobank activity - comprehensive review. Pathol Oncol Res. 2018;24:771–85.
pubmed: 29728978
doi: 10.1007/s12253-018-0418-4
Martins AT, Carneiro I, Monteiro-Reis S, Lobo J, Luís A, Jerónimo CC, et al. Frozen in translation: biobanks as a tool for cancer research. J Intellect Disabil Diagnosis Treat. 2015;3:51–62.
doi: 10.6000/2292-2598.2015.03.02.2
Botling J, Micke P. Biobanking of fresh frozen tissue from clinical surgical specimens: transport logistics, sample selection, and histologic characterization. Methods Mol Biol. 2011;675:299–306.
pubmed: 20949397
doi: 10.1007/978-1-59745-423-0_16
Murray MJ, Coleman N. Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy? Nat Rev Urol. 2019;16:505–6.
pubmed: 31296945
doi: 10.1038/s41585-019-0214-2
Lobo J, Gillis AJM, van den Berg A, Dorssers LCJ, Belge G, Dieckmann KP, et al. Identification and validation model for informative liquid biopsy-based microRNA biomarkers: insights from germ cell tumor in vitro, in vivo and patient-derived data. Cells. 2019;8:1637.
El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–30.
pubmed: 23727028
doi: 10.1016/j.cca.2013.05.022
Kerachian MA, Azghandi M, Mozaffari-Jovin S, Thierry AR. Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA. Clin Epigenetics. 2021;13:193.
pubmed: 34663458
pmcid: 8525023
doi: 10.1186/s13148-021-01182-7
Murray MJ, Watson HL, Ward D, Bailey S, Ferraresso M, Nicholson JC, et al. “Future-proofing” blood processing for measurement of circulating mirnas in samples from biobanks and prospective clinical trials. Cancer Epidemiol Biomark Prev. 2018;27:208–18.
doi: 10.1158/1055-9965.EPI-17-0657
Murray MJ, Scarpini CG, Coleman N. A circulating microRNA panel for malignant germ cell tumor diagnosis and monitoring. In: Bagrodia A, Amatruda JF, editors. Testicular germ cell tumors. Methods in molecular biology. New York: Humana; 2021. p. 225–43.
Myklebust MP, Rosenlund B, Gjengsto P, Bercea BS, Karlsdottir A, Brydoy M, et al. Quantitative PCR measurement of miR-371a-3p and miR-372-p is influenced by hemolysis. Front Genet. 2019;10:463.
pubmed: 31191602
pmcid: 6539204
doi: 10.3389/fgene.2019.00463
Dhudasia MB, Grundmeier RW, Mukhopadhyay S. Essentials of data management: an overview. Pediatr Res. 2021. https://doi.org/10.1038/s41390-021-01389-7 .
Lobo J, Costa AL, Vilela-Salgueiro B, Rodrigues A, Guimaraes R, Cantante M, et al. Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Hum Pathol. 2018;82:113–24.
pubmed: 30041024
doi: 10.1016/j.humpath.2018.07.016
Harari SE, Sassoon DJ, Priemer DS, Jacob JM, Eble JN, Calio A, et al. Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. Urol Oncol. 2017;35:605.e9–e16.
doi: 10.1016/j.urolonc.2017.05.018
Colling R, Protheroe A, Sullivan M, Macpherson R, Tuthill M, Redgwell J, et al. Digital pathology transformation in a supraregional germ cell tumour network. Diagnostics. 2021;11:2191.
pubmed: 34943429
pmcid: 8700654
doi: 10.3390/diagnostics11122191
Wei BR, Simpson RM. Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization. Clin Biochem. 2014;47:274–9.
pubmed: 24362266
doi: 10.1016/j.clinbiochem.2013.12.008
Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol. 2016;13:715–25.
pubmed: 27754472
doi: 10.1038/nrurol.2016.170
Lobo J, Leao R, Jeronimo C, Henrique R. Liquid biopsies in the clinical management of germ cell tumor patients: state-of-the-art and future directions. Int J Mol Sci. 2021;22:2654.
Gillessen S, Sauvé N, Collette L, Daugaard G, De Wit R, Albany C, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021;39:1563–74.
pubmed: 33822655
pmcid: 8099402
doi: 10.1200/JCO.20.03296
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658–86.
pubmed: 30113631
doi: 10.1093/annonc/mdy217
Fonseca A, Faure-Conter C, Murray MJ, Fangusaro J, Bailey S, Goldman S, et al. Pattern of treatment failures in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): a pooled analysis of clinical trials. Neuro Oncol. 2022. https://doi.org/10.1093/neuonc/noac057 .
Piao J, Lafin JT, Scarpini CG, Nuño MM, Syring I, Dieckmann K-P, et al. A multi-institutional pooled analysis demonstrates that circulating miR-371a-3p alone is sufficient for testicular malignant germ cell tumor diagnosis. Clin Genitourin Cancer. 2021;19:469–79.
pubmed: 34629299
doi: 10.1016/j.clgc.2021.08.006
Badia RR, Abe D, Wong D, Singla N, Savelyeva A, Chertack N, et al. Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management. J Urol. 2021;205:137–44.
pubmed: 32856980
doi: 10.1097/JU.0000000000001337
Lafin JT, Murray MJ, Coleman N, Frazier AL, Amatruda JF, Bagrodia A. The road ahead for circulating microRNAs in diagnosis and management of testicular germ cell tumors. Mol Diagn Ther. 2021;25:269–71.
pubmed: 33893623
doi: 10.1007/s40291-021-00526-6
Leão R, Albersen M, Looijenga LH, Tandstad T, Kollmannsberger C, Murray MJ, et al. Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol. 2021;80:456–66.
pubmed: 34175151
doi: 10.1016/j.eururo.2021.06.006
Almstrup K, Lobo J, Morup N, Belge G, Rajpert-De Meyts E, Looijenga LHJ, et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol. 2020;17:201–13.
pubmed: 32157202
doi: 10.1038/s41585-020-0296-x
Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, et al. Germ cell tumor molecular heterogeneity revealed through analysis of primary and metastasis pairs. JCO Precis Oncol. 2020:4:1307–20.
Zhou Z, Cong L, Cong X. Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank. Front Oncol. 2021;11:762184.
pubmed: 35036354
pmcid: 8755639
doi: 10.3389/fonc.2021.762184
Betsou F. Quality assurance and quality control in biobanking. In: Hainaut P, Vaught J, Zatloukal K, Pasterk M, editors. Biobanking of human biospecimens: principles and practice. Cham: Springer International Publishing; 2017. p. 23–49.